TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03976544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
Study: NCT04663737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silmitasertib
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
Study: NCT02013791

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol
Study: NCT02262117

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Description: No specific medical care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: specific treatment
Description: Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
Study: NCT03811002

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04204083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study: NCT00060541

Intervention type: PROCEDURE
Intervention: Laboratory tests

Intervention type: PROCEDURE
Intervention: Radiological exams
Study: NCT00775853

Intervention type: DRUG
Intervention: 6-[18F]Fluorodopamine

Intervention type: DRUG
Intervention: 6-[18F]Fluorodopa

Intervention type: DRUG
Intervention: 13N-Ammonia
Study: NCT00582478

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participants will be followed regularly at 3, 6, 12, and 18-month intervals
Study: NCT02772731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy plus additional Shave Margin
Description: For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial mastectomy
Description: Surgeons will be instructed to close after partial mastectomy with no further excision.
Study: NCT04167553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15136
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Study: NCT04142424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Study: NCT03492424

Intervention type: DEVICE
Intervention: cryotherapy
Description: Subjects will receive focal cryotherapy for treatment of prostate cancer
Study: NCT03533517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventricular Restoration
Description: AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
Study: NCT02919631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Anaplerotic dietary oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Safflower oil
Study: NCT03924869

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT03213678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samotolisib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT00587886

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers.
Study: NCT04142424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Study: NCT03717142

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
Study: NCT04668560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five ways to wellbeing course
Description: A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
Study: NCT04002947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH
Description: Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
Study: NCT04702243

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing for PCD or PID
Description: Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.

Intervention type: OTHER
Intervention: Unaffected Family Member Genetic Testing
Description: Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
Study: NCT01292226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g PO BID for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibody induction
Description: According to manufacturer recommendation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: According to manufacturer recommendation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: According to manufacturer recommendation
Study: NCT03190213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
Study: NCT02013791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol
Study: NCT00001465

Intervention type: DEVICE
Intervention: Toshibia Aquilion One CT
Description: The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
Study: NCT04746794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population-level screening
Description: The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population-level screening
Description: The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.
Study: NCT01028287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
Study: NCT04468984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Tablet/Capsule; Oral or Solution for Subcutaneous Injection
Study: NCT03698071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 6 ml
Study: NCT05531474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Weight Management
Description: The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
Study: NCT02669030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: an FDA-approved sleep aid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group
Study: NCT03251339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11455
Description: Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-Neulasta
Description: Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
Study: NCT02068235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 5mg i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod i.v.
Description: Dose and infusion rate will be adjusted according to the results of the pilot phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod i.v.
Description: Dose and infusion rate will be adjusted according to the results of the pilot phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg tablet
Study: NCT02425163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal shear wave elastography of the prostate
Description: Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal random biopsy of the prostate
Description: TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
Study: NCT01398514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg/day or matched pill placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg/day or matched pill placebo
Study: NCT02268968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Gel
Description: Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
Study: NCT03536533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
Study: NCT02012348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibacterial soap with triclocarban

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibacterial soap + benzalkonium chloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control soap